iBio, Inc. logo

iBio, Inc. (IBIO)

Market Closed
3 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
0. 74
0
0%
$
12.25M Market Cap
- P/E Ratio
0% Div Yield
698,000 Volume
- Eps
$ 0.74
Previous Close
Day Range
0.72 0.76
Year Range
0.64 6.89
Want to track IBIO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio Reports Fiscal Third Quarter 2025 Financial Results

SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.

Globenewswire | 2 months ago
iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Raises $6.2 Million Through Warrant Inducement Transaction

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the “Existing Warrants”), wherein the investors agreed to exercise the Existing Warrants to purchase 5,626,685 shares of common stock at a reduced exercise price of $1.11 per share, resulting in gross proceeds of approximately $6.2 million, before deducting advisory fees and certain other expenses. The Company intends to use the net proceeds for working capital and other general corporate purposes.

Globenewswire | 2 months ago
iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days

Globenewswire | 2 months ago
iBio Reports Fiscal Second Quarter 2025 Financial Results

iBio Reports Fiscal Second Quarter 2025 Financial Results

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress.

Globenewswire | 4 months ago
iBio Reports Fiscal First Quarter 2025 Financial Results

iBio Reports Fiscal First Quarter 2025 Financial Results

Advanced myostatin program with dosing underway in non-human primate study Advanced myostatin program with dosing underway in non-human primate study

Globenewswire | 7 months ago
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update.

Globenewswire | 9 months ago
iBio to Participate in Upcoming Investor Conferences

iBio to Participate in Upcoming Investor Conferences

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., and Chief Financial Officer, Felipe Duran, will participate in upcoming investor conferences.

Globenewswire | 10 months ago
iBio Closes Sale of Manufacturing Facility in Texas

iBio Closes Sale of Manufacturing Facility in Texas

–  The sale of the facility eliminates $13.2M of secured debt – –  Completes iBio's transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapeutics, today announced the closing of the sale of its manufacturing facility located in Bryan, Texas (the “Property”) to the Board of Regents of the Texas A&M University System for $8.5 million. Following the issuance of pre-funded warrants having a value of $4.5 million to the lender, Woodforest National Bank, iBio and its wholly owned subsidiary, iBio CDMO LLC, has met all of the conditions of the settlement agreement releasing the Company and its subsidiary of all obligations with respect to the debt secured by the Property.

Globenewswire | 1 year ago